Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - A novel potent and orally active immunosuppressive agent

International Immunopharmacology

Volumn 1, Issue 6, 2001, Pages 1199-1210

  Bantia, Shanta ^a   Miller, Patrick J ^a   Parker, Cynthia D ^a   Ananth, Sandya L ^a   Horn, Lashun L ^a   Kilpatrick, John M ^a   Morris, Philip E ^a   Hutchison, Tracy L ^a   Montgomery, John A ^a   Sandhu, Jasbir S ^b  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Graft vs. host disease; Immunomodulators; In vivo animal models; T Lymphocytes

Indexed keywords

9 (3 THENYL) 9 DEAZAGUANINE; DEOXYGUANOSINE; IMMUCILLIN H; IMMUNOSUPPRESSIVE AGENT; PELDESINE; PHYTOHEMAGGLUTININ; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; ENZYME INHIBITORS; GRAFT VS HOST REACTION; GUANOSINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; INJECTIONS, INTRAVENOUS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, SCID; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; PYRROLES; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 0035026893     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00056-X     Document Type: Article

References (33)

1. Martin D.W., Gelfand E.W. Biochemistry of diseases of immunodevelopment. Annu. Rev. Biochem. 50:1981;845-877.
2. Kredich N.M., Hershfield M.S. Immunodeficiency caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S. The metabolic basis of inherited disease. 1989;1045-1075 McGraw-Hill, New York.
3. Giblett E.R., Ammann A.J., Wara D.W., Sandman R., Diamond L.K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1:1975;1010-1013.
4. Cohen A., Doyle D., Martin D.W., Ammann A.J. Abnormal purine metabolism and purine overproduction in a patient deficient of purine nucleoside phosphorylase. N. Engl. J. Med. 295:1976;1449-1454.
5. Siegenbeek van Heukelom L.K., Staal G.E.J., Stoop J.W., Zegers B.J.M. An abnormal form of a purine nucleoside phosphorylase in a family with a child with severe defective T-cell and normal B-cell immunity. Clin. Chim. Acta. 72:1976;117-124.
6. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev. 3:1991;45-81.
7. Kazmers I.S., Mitchell B.S., DaDonna P.E., Wotring I.I., Townsend L.B., Kelly W.N. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T-lymphocytes. Science. 214:1981;1137-1139.
8. Sircar J.C., Gilbertsen R.B. Purine nucleoside phosphorylase (PNP) inhibitors: potentially selective immunosuppressive agents. Drugs Future. 13:1988;653-668.
9. Krenitsky T.A., Tuttle J.V., Koszalka G.W., Chen I.S., Beacham L.M.et al. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J. Biol. Chem. 251:1976;4055-4061.
10. Gilbertsen R.B., Scott M.E., Dong M.K., Kossarek L.M., Bennett M.K.et al. Preliminary report on 8-amino-9-(2-thienylmethyl) guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor. Agents Actions. 21:1987;272-274.
11. Gilbertsen R.B., Josyula U., Sircar J.C., Dong M.K., Wilburn D.J., Conroy M.C. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955. Biochem. Pharmacol. 44:1992;996-999.
12. Bantia S., Montgomery J.A., Johnson H.G., Walsh G.M. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology. 35:1996;53-63.
13. Bennett L.L. Jr., Allan P.W., Noker P.E., Rose L.M., Niwas S.et al. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. J. Pharmacol. Exp. Ther. 266:1993;707-714.
14. Eriksson S., Thelander L., Kaerman M. Allosteric regulation of calf thymus ribonucleoside diphosphate reductase. Biochemistry. 18:1979;2946-2952.
15. Wilburn D.J., Dong M.K., Gilbertsen R.B. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors: I. Suppression of the human mixed lymphocyte reaction (MLR). Agents Actions. 39:1993;C96-C98. (special conference issue).
16. Conry R.M., Bantia S., Turner H.S., Barlow D.L., Allen K.O.et al. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. Immunopharmacology. 40:1998;1-9.
17. Viegas T.X., Omura G.A., Stoltz R.R., Kisicki J. Pharmacokinetics and pharmacodynamics of Peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 40:2000;410-420.
18. Miles R.W., Tyler P.C., Furneaux R.H., Bagdassarian C.K., Schramm V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 37:1998;8615-8621.
19. Sandhu J.S., Gorczynski R., Shpitz B., Gallinger S., Nguyen H., Hozumi N.A. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation. 60:1995;179-184.
20. Krenitsky T.A., Elion G.B., Henderson A.M., Hitchings G.H. Inhibition of human purine nucleoside phosphorylase. J. Biol. Chem. 243:1968;2876-2881.
21. Madsen M., Johnson H.E. A methodological study of E-rosette formation using AET-treated sheep erythrocytes. J. Immunol. Methods. 27:1979;61-74.
22. Sherman P.A., Fyfe J.A. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal. Biochem. 180:1989;222-226.
23. Braida M., Knop J. Effect of cyclosporin A on the T-effector and T-suppressor cell response in contact sensitivity. Immunology. 59:1986;503-507.
24. Walsh G.M., Reddy N.S., Bantia S., Babu Y.S., Montgomery J.A. Development of inhibitors of purine nucleoside phosphorylase. Hematol. Rev. 8:1994;87-97.
25. Roudebush R.E., Bryant H.U. Pharmacologic manipulation of graft versus host induced splenomegaly. Agents Action. 35:1992;260-267.
26. Mosier D.E., Guilizia R.J., Baird S.M., Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 335:1988;256-259.
27. Dong M.K., Gilbertsen R.B. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors: II. Effects on nucleoside catabolism in human and rat blood in vitro. Agents Actions. 39:1993;C99-C101. (special conference issue).
28. Morris P.E., Omura G.A. Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis. Curr. Pharm. Des. 6:2000;943-959.
29. Simmonds H.A., Fairbanks L.D., Morris G.S., Morgan G., Watson A.et al. Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. Arch. Dis. Child. 62:1987;385-391.
30. Arpaia E., Benveniste P., Di Cristofano A., Gu Y., Dalal I.et al. Mitochondrial basis for immune deficiency: evidence from purine nucleoside phosphorylase-deficient mice. J. Exp. Med. 191:2000;2197-2207.
31. Scharenberg J.G.M., Rijkers G.T., Spaapen L.J.M., Toebes E.A.H., Rijksenet al. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages. Int. J. Immunopharmacol. 10:1988;675-686.
32. Sandhu J.S., Boynton E., Gorczynski R., Hozumi N. The use of SCID mice in biotechnology and as a model for human disease. Crit. Rev. Biotechnol. 16:1996;95-118.
33. Chatenoud L. Anti-CD3 and anti-TCR monoclonal antibodies. Bach J.F. T-cell directed immune intervention. 1993;157-169 Blackwell, Oxford.